Implantica, a medtech group bringing advanced technology into the body, has appointed a new commercial team comprising four sales and marketing professionals.
Stefan Vogt is joining as Chief Commercial Officer (CCO) with responsibility for the development and execution of commercialisation at Implantica. Vogt was previously CCO at LifeWatch and director international business at Preventice Solutions, both digital health companies providing remote cardiac monitoring of patients. He was VP corporate marketing at the world’s largest dental implant company, Institut Straumann.
Steffen Schanz joins as VP marketing and product management, and is responsible for defining and implementing marketing strategies. He was previously director marketing and product management at Spinal Kinetics. Prior to that he was director product management for various treatment areas at Karl Storz, including the reconstruction/implant business.
Gerhard Landwehr has been appointed VP business development for DACH and UK. He has over 10 years’ experience in leading positions commercialising anti-reflux implants. He was previously general manager Europe for EndoStim.
Henric Forsell is VP commercial development at Implantica and is responsible for developing and executing sales initiatives, market research and after-sales support. He has been with the company since 2018.
Stephan Siegenthaler has been promoted to Chief Strategy Officer and will oversee the process.
“Our new commercialisation team is ready to advance our go-to-market strategy for RefluxStop,” said Peter Forsell, CEO of Implantica.
RefluxStop is an implant for the prevention of gastroesophageal reflux.
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.